Expensive cancer drugs with modest benefit ignite debate over solutions

Journal of the National Cancer Institute

Volumn 100, Issue 19, 2008, Pages 1347-1349

  Sinha, Gunjan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; TAMOXIFEN;

COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; HUMAN; INSURANCE; NOTE; PRACTICE GUIDELINE; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; INSURANCE COVERAGE; PRACTICE GUIDELINES AS TOPIC; TAMOXIFEN; TREATMENT OUTCOME; UNITED STATES;

EID: 69949167150     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn357     Document Type: Note

References (0)